Alumis Inc Market Cap ($847.80 Million)
Market Cap & Net Worth: Alumis Inc (ALMS)
Alumis Inc market cap. Alumis Inc (NASDAQ:ALMS) has a market capitalization of $847.80 Million ($847.80 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9328 globally and #2615 in its home market, demonstrating a -1.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alumis Inc's stock price $6.55 by its total outstanding shares 129435239 (129.44 Million). Also see cash flow conversion of Alumis Inc for how efficiently the company converts equity into cash flow.
Alumis Inc Market Cap History (2024–2026)
Alumis Inc market cap history from 2024 to 2026. Data shows change from $1.02 Billion to $847.80 Million (-31.55% CAGR). Check Alumis Inc stock quote for real-time trading data and today's change.
Index Memberships
Alumis Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.03% | #266 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #990 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.05% | #155 of 263 |
Weight: Alumis Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Alumis Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alumis Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Alumis Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
52.53x
Alumis Inc's market cap is 52.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $1.26 Billion | $24.05 Million | -$243.32 Million | 52.53x | N/A |
Competitor Companies of ALMS by Market Capitalization
Companies near Alumis Inc in the global market cap rankings as of November 5, 2026. Also see Alumis Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Alumis Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Alumis Inc (2024–2026)
Market capitalization of Alumis Inc from 2024 to today. Between 2024 and today, Alumis Inc's market cap moved from $1.02 Billion to $ 847.80 Million, with a yearly change of -31.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $847.80 Million | -32.89% |
| 2025 | $1.26 Billion | +24.17% |
| 2024 | $1.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Alumis Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $847.80 Million USD |
| MoneyControl | $847.80 Million USD |
| MarketWatch | $847.80 Million USD |
| marketcap.company | $847.80 Million USD |
| Reuters | $847.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alumis Inc
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment o… Read more